Ipca Laboratories and Bhami's Research Laboratory (BRL) announced a definitive global licensing agreement on June 12, 2026, granting Ipca access to BRL's proprietary high-concentration subcutaneous biologics delivery platform. This collaboration aims to develop and commercialize multiple monoclonal antibody products targeting oncology and inflammatory diseases. The partnership leverages BRL's novel formulation technology alongside Ipca's established scientific capabilities to accelerate the creation of affordable biologics for global markets.

Under the agreement, BRL is responsible for proof of concept and formulation development, while Ipca will handle further research and development, clinical trials, commercial manufacturing, and product launch. The licensing territory covers worldwide markets. Financial terms include a defined milestone fee for BRL pertaining to technology transfer, followed by royalties on net sales upon commercialization of the products.

Pranay Godha, MD & CEO of Ipca Laboratories, stated that pairing Ipca's established science with BRL's platform accelerates the development of affordable biologics for patients battling cancer and autoimmune diseases. Dr Suryakanth M Pai, Co-founder and CEO of BRL, emphasized that the strategic partnership is designed to make patient care convenient, affordable, and safe by expanding the reach of their patented subcutaneous protein delivery platform technology.

Deal Snapshot

Ipca, established in 1949, is focusing on expanding its biosimilar capabilities, specifically targeting anti-cancer and anti-inflammatory monoclonal antibodies. The company has established a bio-manufacturing facility in Pithampur and an R&D facility in Mumbai to support these initiatives. This new subcutaneous formulation development is expected to enhance Ipca's product portfolio across key markets including the USA, UK, EU, Japan, Canada, and India.

ipca laboratories witnessed a notable block trade on the National Stock Exchange (NSE), with approximately 5,51,482 shares changing hands in a single transaction. The deal was executed at a price of ₹1,638.30 per share, aggregating to a total transaction value of ₹90.35 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded on the NSE:

Block trades of this scale are typically executed by institutional participants and are carried out through a separate trading window on the exchange, outside the standard order book mechanism. Such transactions are closely monitored by market participants as they may reflect significant institutional interest in the company's stock.